Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial.
Osteoporosis is a major health issue facing postmenopausal women. Increased production of pro-inflammatory cytokines resulting from declining estrogen leads to increased bone resorption. Nutrition can have a positive impact on osteoporosis prevention and amelioration. The objective of this study was to investigate the impact of targeted phytochemicals and nutrients essential for bone health on bone turnover markers in healthy postmenopausal women. In this 14-week, single-blinded, 2-arm placebo-controlled pilot study, all women were instructed to consume a modified Mediterranean-style low-glycemic-load diet and to engage in limited aerobic exercise; 17 randomized to the placebo and 16 to the treatment arm (receiving 200 mg hop rho iso-alpha acids, 100 mg berberine sulfate trihydrate, 500 IU vitamin D(3) and 500 microg vitamin K(1), twice daily). Thirty-two women completed the study. Baseline nutrient intake did not differ between arms. At 14 weeks, the treatment arm exhibited an estimated 31% mean reduction (P = 0.02) in serum osteocalcin (a marker of bone turnover), whereas the placebo arm exhibited a 19% increase (P = 0.03) compared to baseline. Serum 25-hydroxyvitamin D (25(OH)D) increased by 13% (P = 0.24) in the treatment arm and decreased by 25% (P < 0.01) in the placebo arm. The between-arm differences for OC and 25(OH)D were statistically significant. Serum IGF-I was increased in both arms, but the increase was more significant in the treatment arm at 14 weeks (P < 0.01). Treatment with hop rho iso-alpha acids, berberine sulfate trihydrate, vitamin D(3) and vitamin K(1) produced a more favorable bone biomarker profile that supports a healthy bone metabolism.
Holick
Michael F
MF
Boston University School of Medicine, Boston, MA, USA.
Lamb
Joseph J
JJ
Lerman
Robert H
RH
Konda
Veera R
VR
Darland
Gary
G
Minich
Deanna M
DM
Desai
Anuradha
A
Chen
Tai C
TC
Austin
Melissa
M
Kornberg
Jacob
J
Chang
Jyh-Lurn
JL
Hsi
Alex
A
Bland
Jeffrey S
JS
Tripp
Matthew L
ML
D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D001599:Berberine / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood / Q000652:urine; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D016723:Bone Remodeling; D002112:Calcifediol / Q000097:blood; D002762:Cholecalciferol / Q000008:administration & dosage; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D027582:Humulus / Q000737:chemistry; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D008517:Phytotherapy; D010865:Pilot Projects; D010936:Plant Extracts / Q000008:administration & dosage; D017698:Postmenopause; D016037:Single-Blind Method; D010837:Vitamin K 1 / Q000008:administration & dosage
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D010936:Plant Extracts; D001599:Berberine; D015675:Osteocalcin; D002762:Cholecalciferol; D015652:25-Hydroxyvitamin D 2; D007334:Insulin-Like Growth Factor I; D010837:Vitamin K 1; D002112:Calcifediol